Korro Bio (KRRO) Stock Price, News & Analysis

Company Overview

Korro Bio, Inc. is a biotechnology company developing RNA editing medicines for the treatment of genetic diseases. The company’s approach is designed to make targeted changes to messenger RNA (mRNA), potentially correcting disease-causing mutations without permanently altering a patient’s DNA.

Korro Bio’s technology platform, known as Oligonucleotide Promoted Editing of RNA, or OPERA, uses engineered oligonucleotides to guide naturally occurring cellular RNA-editing processes. The platform is intended to support the development of medicines for diseases involving the liver and other tissues.

The company’s lead clinical program, KRRO-110, is being developed for alpha-1 antitrypsin deficiency, an inherited disorder caused by mutations in the SERPINA1 gene. The program is designed to edit the relevant mRNA and promote production of functional alpha-1 antitrypsin protein. Korro Bio is based in Massachusetts and focuses primarily on research and clinical development of RNA editing therapeutics.

Key Stats

• Today's Range: $9.41 to $9.89
• 50-Day Range: $9.51 to $14.07
• 52-Week Range: $5.20 to $55.89
• Volume: 49,853 shs
• Average Volume: 190,714 shs
• Market Capitalization: $146.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.71
• Consensus Rating: Moderate Buy

Korro Bio Stock Analysis - MarketRank™

Korro Bio scored higher than 42% of companies evaluated by MarketBeat, and ranked 619th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Korro Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 3 strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Korro Bio has a consensus price target of $16.71, representing about 70.9% upside from its current price of $9.78.

Amount of Analyst Coverage

Korro Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Korro Bio are expected to grow in the coming year, from ($4.95) to ($4.46) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Korro Bio is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Korro Bio is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Korro Bio has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.07% of the float of Korro Bio has been sold short.

Short Interest Ratio / Days to Cover

Korro Bio has a short interest ratio ("days to cover") of 11.91, which indicates bearish sentiment.

Change versus previous month

Short interest in Korro Bio has recently increased by 4.60%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Korro Bio does not currently pay a dividend.

Dividend Growth

Korro Bio does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Korro Bio insiders have sold 740.21% more of their company's stock than they have bought. Specifically, they have bought $78,815.00 in company stock and sold $662,214.00 in company stock.

Percentage Held by Insiders

4.80% of the stock of Korro Bio is held by insiders.

Percentage Held by Institutions

13.18% of the stock of Korro Bio is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KRRO
• Previous Symbol: NASDAQ:KRRO
• CIK: 1703647
• Web: www.korrobio.com
• Phone: 781-315-4600
• Fax: N/A
• Employees: 57
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Korro Bio: $16.71
• High Price Target: $23.00
• Low Price Target: $10.00
• Potential Upside/Downside: +68.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($10.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$117.26 million
• Net Margins: N/A
• Pretax Margin: -4,441.85%
• Return on Equity: -114.26%
• Return on Assets: -68.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.55
• Quick Ratio: 9.55

Sales & Book Value

• Annual Sales: $6.39 million
• Price / Sales: 22.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.46 per share
• Price / Book: 1.81

Miscellaneous

• Outstanding Shares: 14,730,000
• Free Float: 14,019,000
• Market Cap: $145.89 million
• Optionable: No Data
• Beta: 3.13